Cangrelor (Kengrexal)

P2Y12 platelet inhibitor (antiplatelet agent)

Cangrelor (Kengrexal)

Forms and strengths
Form: TabletStrength: 50 mg per vial
Print

Indication

  • Cangrelor is used to reduce the risk of thrombotic cardiovascular events, including periprocedural heart attack, repeat coronary revascularization, and stent thrombosis, in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI).
  • Reserved for patients who have not already been treated with an oral P2Y12 platelet inhibitor and are not receiving a glycoprotein IIb/IIIa inhibitor.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.